menu
    • menu
    [{"orgOrder":0,"company":"RevOpsis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"DENMARK","productType":"Large molecule","year":"2024","type":"Funding","leadProduct":"RO-104","moa":"","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"RevOpsis Therapeutics","amount2":0.02,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0.02,"dosageForm":"","sponsorNew":"RevOpsis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"RevOpsis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"RevOpsis Therapeutics","sponsor":"Kemwell Biopharma Private Limited","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWEDEN","productType":"Large molecule","year":"2024","type":"Partnership","leadProduct":"RO-104","moa":"","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"RevOpsis Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"RevOpsis Therapeutics \/ RevOpsis Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"RevOpsis Therapeutics \/ RevOpsis Therapeutics"},{"orgOrder":0,"company":"RevOpsis Therapeutics","sponsor":"National Eye Institute","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"DENMARK","productType":"Large molecule","year":"2024","type":"Funding","leadProduct":"RO-104","moa":"","graph1":"Technology","graph2":"Approved","graph3":"RevOpsis Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"RevOpsis Therapeutics \/ National Eye Institute","highestDevelopmentStatusID":"12","companyTruncated":"RevOpsis Therapeutics \/ National Eye Institute"},{"orgOrder":0,"company":"RevOpsis Therapeutics","sponsor":"Asimov","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Licensing Agreement","leadProduct":"RO-104","moa":"","graph1":"Technology","graph2":"Approved","graph3":"RevOpsis Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"RevOpsis Therapeutics \/ RevOpsis Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"RevOpsis Therapeutics \/ RevOpsis Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by RevOpsis Therapeutics

    Menu

    RevOpsis Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            RevOpsis Therapeutics

                            Denmark arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            RevOpsis Therapeutics

                            Denmark arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RO-104

                            Therapeutic Area : Ophthalmology

                            Study Phase : Preclinical

                            Recipient : Asimov

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Asimov Signs Agreement for High Titer Multispecific Cell Line Licensing with RevOpsis

                            Details : RevOpsis will integrate the CHO Edge System in the development and commercialization of its first-in-class fully modular tri-specific biologic, RO-104, for the treatment of retinal vascular diseases.

                            Brand Name : RO-104

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            November 19, 2024

                            Lead Product(s) : RO-104

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Preclinical

                            Recipient : Asimov

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            RevOpsis Therapeutics

                            Denmark arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            RevOpsis Therapeutics

                            Denmark arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RO-104

                            Therapeutic Area : Ophthalmology

                            Study Phase : Preclinical

                            Sponsor : National Eye Institute

                            Deal Size : $1.8 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            RevOpsis Wins $1.8M Grant for Ophthalmic Therapy R&D Advancement

                            Details : The SBIR grant will fund critical R&D activities, including multidose GMP toxicology studies in nonhuman primates for RO-104, a first-in-class fully human modular tri-specific biologic.

                            Brand Name : RO-104

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 15, 2024

                            Lead Product(s) : RO-104

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Preclinical

                            Sponsor : National Eye Institute

                            Deal Size : $1.8 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            RevOpsis Therapeutics

                            Denmark arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            RevOpsis Therapeutics

                            Denmark arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RO-104

                            Therapeutic Area : Ophthalmology

                            Study Phase : IND Enabling

                            Recipient : Kemwell Biopharma Private Limited

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            RevOpsis and Kemwell Form Strategic Manufacturing Partnership for Biologics

                            Details : Through the partnership, RevOpsis is well-positioned to advance the clinical development of RO-104, a first-in-class lead candidate for the treatment of neovascular age-related macular degeneration.

                            Brand Name : RO-104

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 17, 2024

                            Lead Product(s) : RO-104

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : IND Enabling

                            Recipient : Kemwell Biopharma Private Limited

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            RevOpsis Therapeutics

                            Denmark arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            RevOpsis Therapeutics

                            Denmark arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RO-104

                            Therapeutic Area : Ophthalmology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : $16.5 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            RevOpsis Secures Seed Funding for First-in-Class Tri-Specific Therapy for Neovascular AMD

                            Details : Through the funding, RevOpsis is well positioned to advance clinical development of RO-104, first-in-class lead candidate for the treatment of neovascular age-related macular degeneration.

                            Brand Name : RO-104

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            April 25, 2024

                            Lead Product(s) : RO-104

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : $16.5 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth